770
Views
16
CrossRef citations to date
0
Altmetric
Review

Monoclonal antibodies for renal diseases: current concepts and ongoing treatments

, , , , &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Rossella Siligato, Valeria Cernaro, Chiara Nardi, Francesca De Gregorio, Guido Gembillo, Giuseppe Costantino, Giovanni Conti, Michele Buemi & Domenico Santoro. (2018) Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis. Expert Opinion on Investigational Drugs 27:11, pages 839-879.
Read now
Viviana Lacava, Vincenzo Pellicanò, Carmen Ferrajolo, Valeria Cernaro, Luca Visconti, Giovanni Conti, Michele Buemi & Domenico Santoro. (2017) Novel avenues for treating diabetic nephropathy: new investigational drugs. Expert Opinion on Investigational Drugs 26:4, pages 445-462.
Read now

Articles from other publishers (14)

Prerna Sharma, Rahul V. Joshi, Robert Pritchard, Kevin Xu & Maya A. Eicher. (2023) Therapeutic Antibodies in Medicine. Molecules 28:18, pages 6438.
Crossref
Iyad Mansour, Sangeetha Murugapandian, Bekir Tanriover & Bijin Thajudeen. (2023) Contemporary Monoclonal Antibody Utilization in Glomerular Diseases. Mayo Clinic Proceedings: Innovations, Quality & Outcomes 7:4, pages 276-290.
Crossref
Gianmarco Sabiu, Vivek Kasinath, Sungwook Jung, Xiaofei Li, George C Tsokos & Reza Abdi. (2023) Targeted nanotherapy for kidney diseases: a comprehensive review. Nephrology Dialysis Transplantation 38:6, pages 1385-1396.
Crossref
Ana B. Nunez-Nescolarde, David J. Nikolic-Paterson & Alexander N. Combes. (2022) Human Kidney Organoids and Tubuloids as Models of Complex Kidney Disease. The American Journal of Pathology 192:5, pages 738-749.
Crossref
Nicola Wanner, Thomas Eden, Nastassia Liaukouskaya & Friedrich Koch-Nolte. (2021) Nanobodies: new avenue to treat kidney disease. Cell and Tissue Research 385:2, pages 445-456.
Crossref
Vsevolod Skvortsov, Aleksandr Tumarenko, Georgiy Malyakin & Ellina Golieva. (2020) Modern approaches to pharmacotherapy of chronic glomerulonephritis. Spravočnik vrača obŝej praktiki (Journal of Family Medicine):8, pages 36-45.
Crossref
Joana Eugénio Santos, David Fiel, Ricardo Santos, Rita Vicente, Rute Aguiar, Iolanda Santos, Manuel Amoedo & Carlos Pires. (2020) Rituximab use in adult glomerulopathies and its rationale. Brazilian Journal of Nephrology 42:1, pages 77-93.
Crossref
Ravneet Bajwa, John A. DePalma, Taimoor Khan, Anmol Cheema, Sheila A. Kalathil, Mohammad A. Hossain, Attiya Haroon, Anne Madhurima, Min Zheng, Ali Nayer & Arif Asif. (2018) C3 Glomerulopathy and Atypical Hemolytic Uremic Syndrome: Two Important Manifestations of Complement System Dysfunction. Case Reports in Nephrology and Dialysis 8:1, pages 25-34.
Crossref
Franca Iorember, Diego Aviles, Mahmoud Kallash & Oluwatoyin Bamgbola. (2017) Cost analysis on the use of rituximab and calcineurin inhibitors in children and adolescents with steroid-dependent nephrotic syndrome. Pediatric Nephrology 33:2, pages 261-267.
Crossref
Vladimir Tesar, Kazimierz Ciechanowski, York Pei, Irina Barash, Megan Shannon, Ray Li, Jason H. Williams, Matteo Levisetti, Steven Arkin & Andreas Serra. (2017) Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease. Journal of the American Society of Nephrology 28:11, pages 3404-3413.
Crossref
Andreas Kronbichler, Martin Windpessl, Herwig Pieringer & David R.W. Jayne. (2017) Rituximab for immunologic renal disease: What the nephrologist needs to know. Autoimmunity Reviews 16:6, pages 633-643.
Crossref
Chengjung Lai, Cristina Martin-Higueras & Eduardo Salido. 2017. Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders. Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders 159 190 .
Luca Visconti, Domenico Santoro, Valeria Cernaro, Michele Buemi & Antonio Lacquaniti. (2016) Kidney-lung connections in acute and chronic diseases: current perspectives. Journal of Nephrology 29:3, pages 341-348.
Crossref
Agnieszka Pozdzik, Ingrid Beukinga, Chunyan Gu-Trantien, Karen Willard-Gallo, Joëlle Nortier & Olivier Pradier. (2016) Circulating (CD3 − CD19 + CD20 − IgD − CD27 high CD38 high ) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy? . Mediators of Inflammation 2016, pages 1-10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.